In past 5 years, ever the global pandemic of COVID-19, as a new infectious disease, has undergone extensive and in-depth research on its etiology, pathology, diagnosis, prevention and treatment, as well as integrative Chinese and western medicine. The prevention, treatment and rehabilitation of integrative Chinese and Western medicine in mainland China has played an important role in management of the epidemic. One of its advantages in Chinese Medicine is that even when the cause of the infectious disease is unknown, based on the theory of Chinese medicine and past practical experience, Chinese medicine can have its own diagnosis and treatment plan, but the disadvantage is that there is a lack of modern clinical and scientific evidences. Although vaccines have been emerged one after another, and pandemic is gone, COVID-19 is still one of season diseases, and the effectiveness and safety of vaccines needs further observation, especially for people who are elder age and complicated with other diseases. This presentation intends to review the research progress and existing problems of COVID-19 in Chinese and Western medicine, focus on prevention, treatment and rehabilitation of COVID-19 by Chinese herbal medicine, and explore its scientific and clinical evidence in multicompounds and multitargets. Based on our literature review and our studies, we published several review papers and clinical studies, and awarded a Hong Kong Government grant to support our RCT study for prevention of COVID-19 by Chinese herbal medicine which will present the part of the results in the conference. (Up to 250 words)
Biography
Dr. Feng Yibin is currently a professor and Director of the School of Chinese Medicine, University of Hong Kong. Mainly engaged in the research, teaching and clinical consultation of integrated Chinese and Western medicine in the prevention and treatment of cancer and metabolic diseases.
He has published more than 600 various kind of publications, among which over 200 SCI papers in reputable international journals. He was listed as a Highly Cited Researcher (1/1000, Clarivate Analytics 2024) and the top 1% scholars for 8 consecutive years (ESI), and is also ranked in the top 2% scholar at Stanford University. (Up to 100 words)